Intra-Arterial Thrombolytic Therapy Is Not a Therapeutic Option for Filler-Related Central Retinal Artery Occlusion

Facial Plast Surg. 2018 Jun;34(3):325-329. doi: 10.1055/s-0037-1621730. Epub 2018 Jan 29.

Abstract

Cosmetic facial filler-related central retinal artery occlusion (CRAO) is a devastating complication of facial hyaluronic acid (HA) injection and can be managed by intra-arterial thrombolytic therapy (IATT). The authors report on a 20-year-old woman who developed unilateral CRAO due to facial HA injection and who, despite prompt IATT, lost vision. A review of the related literature found 14 other female patients who developed cosmetic facial filler-related CRAO and accepted IATT management. In no case was vision loss clinically improved. IATT is not an effective preventive treatment of dermal filler-associated CRAO. The authors suggest careful preprocedural patient selection to prevent this complication.

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Angiography
  • Blindness / etiology
  • Dermal Fillers / adverse effects*
  • Female
  • Humans
  • Hyaluronic Acid / adverse effects*
  • Hyaluronoglucosaminidase / administration & dosage
  • Hyaluronoglucosaminidase / therapeutic use*
  • Infusions, Intra-Arterial
  • Retinal Artery Occlusion / chemically induced*
  • Retinal Artery Occlusion / diagnostic imaging
  • Retinal Artery Occlusion / drug therapy*
  • Treatment Failure
  • Urokinase-Type Plasminogen Activator / administration & dosage
  • Urokinase-Type Plasminogen Activator / therapeutic use*
  • Young Adult

Substances

  • Dermal Fillers
  • Hyaluronic Acid
  • Hyaluronoglucosaminidase
  • Urokinase-Type Plasminogen Activator